AUTHORS
Francesca Crupi, MD, Paola Guglielmelli, MD, PhD2, Naseema Gangat, MBBS3, Animesh Pardanani, PhD, MBBS4, Niccolò Bartalucci, PhD5, Alessio Enderti, MSC6, Mithun Shah, MD, PhD7, Hassan B Alkhateeb, M.D.8, Alfonso Piciocchi, MS9, Stefano Soddu10, Alessandro Rambaldi, MD11, Giovanni Caocci, MD12, Monica Bocchia13, Ernesta Audisio, MD14, Antonio Curti Sr, MD15, Fabrizio Pane Sr, MD16, Erika Borlenghi, MD17, Pellegrino Musto, MD18, Patrizia Chiusolo, MD19, Elisa Coviello20, Daniela Cilloni, MD21, Mirko Lomi22, Giuseppe Gaetano Loscocco, MD, PhD23, Francesco Mannelli24, Ayalew Tefferi, MD25, Alessandro Vannucchi, MD26
AFFILIATIONS
1 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
2 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
3 Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
4 Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
5 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
6 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
7 Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
8 Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
9 GIMEMA Foundation, Rome, Italy
10 GIMEMA Foundation, Rome, Italy
11 Fondazione per la Ricerca Ospedale di Bergamo (FROM), Bergamo, Italy
12 Hematology and Bone Marrow Transplant Center, “A. Businco” Hospital, ARNAS “G. Brotzu”, Cagliari, Italy
13 Hematology Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy
14 Hematology Department, Città della Salute e della Scienza di Torino, Turin, Italy
15 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Institute of Hematology “Seràgnoli”, Bologna, Italy
16 Department of Clinical Medicine and Surgery, Hematology Division, University of Napoli 'Federico II”, Napoli, Italy
17 Hematology Unit, ERN/EuroBloodNet, ASST Spedali Civili di Brescia, Brescia, Italy
18 11Department of Precision and Regenerative Medicine and Ionian Area, 'Aldo Moro' University School of Medicine, and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy
19 Hematology Department, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy
20 15Hematology and Stem Cell Therapies, IRCCS Azienda Ospedaliera Metropolitana, Ospedale Policlinico San Martino, Genoa, Italy
21 Department of Clinical and Biological Sciences, University of Turin, AO Ordine Mauriziano, Turin, Italy
22 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
23 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
24 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
25 Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
26 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
ABSTRACT
Background. Blast phase-myeloproliferative neoplasms (MPN-BP) is characterized by genetic complexity, intrinsic chemoresistance and dismal prognosis. We reported favorable results of the ENABLE trial (Vannucchi et al, ASH 2025), a prospective cohort of MPN-BP pts treated with decitabine plus venetoclax. The performance of molecular prognostic models developed in de novo acute myeloid leukemia (AML) patients (pts) treated with venetoclax plus hypomethylating agents (VEN/HMA) – namely ELN 2024 (Dohner H, Blood 2024), ELN 2024 refined, (Lachowiez C, Blood 2024) and Mayo (Gangat N, AJH 2026), remains poorly defined. Gangat et al (AJH 2026) found a negative impact of TP53 mutation and circulating blasts >20% among 82 pts with accelerated/BP MPN treated frontline with VEN/HMA.
Aims We aimed to characterize the mutational landscape of ENABLE pts, analyze association of baseline molecular features with overall survival (OS), and evaluate current prognostic models.
Methods. Baseline NGS data for myeloid gene mutations were available in 92/101 enrolled pts. Only genes mutated in >5 pts were considered. The median variant allele frequency (VAF) of each mutated gene was determined, and VAF was subsequently analysed as a continuous variable in Cox models. OS was estimated using the Kaplan–Meier method. Findings were compared with an independent Mayo Clinic cohort of 82 pts (Gangat et al., AJH 2026).
Results. The most frequently mutated genes were JAK2 (74%), ASXL1 (37%), TP53 (28%), TET2 (26%), SRSF2 (25%), RUNX1 (22%), EZH2 (20%), DNMT3A, CALR, NRAS and STAG2 (13% each), and IDH2 (11%). NPM1 was 5% and FLT3-ITD none. TP53 and DNMT3A rarely co-occurred (3/26 TP53-mutated pts). Median VAF was >50% only for driver mutations MPL (75%, IQR 35–91) and CALR (53%, IQR 48–58), while JAK2 showed a borderline value (48%, IQR 29–63). Among myeloid mutations, TP53 displayed the highest allelic burden (median VAF 58%, IQR 33–80), consistent with high prevalence of multi-hit TP53 (17/26, 65%). RAS-pathway mutations showed low VAFs (NRAS 31%, IQR 8–40; KRAS 9%, IQR 3–21), consistent with subclonal events. Other commonly mutated genes showed intermediate VAF: ASXL1 (44%, IQR 34–47), SRSF2 (46%, IQR 34–55), and DNMT3A (40%, IQR 37–45). TET2 VAF (median 45%, IQR 43–50 as a continuous variable resulted significant predictor of OS (HR 1.03, 95% CI 1.00–1.06, p=0.030). All three scores considered -ELN 2024, ELN 2024 ref, and Mayo- showed limited performance in our cohort, with C-index of 0.63, 0.62 and 0.58, respectively, notably failing to adequately resolve intermediate versus adverse group.
In univariate analysis TP53 predicted inferior OS (HR 2.13, 95% CI 1.23-3.69, p=0.007), whereas DNMT3A superior OS (HR 0.31, 95% CI 0.11-0.86, p=0.025). Both mutations retained independent significance in multivariable analysis: TP53, HR 2.17 (95% CI 1.25-3.78, p=0.0065 and DNMT3A HR 0.30 (95% CI 0.11-0.84, p=0.022). PTPN11 was significant in univariate analysis, however, because 5/7 PTPN11-mutated pts had concurrent TP53 mutation, significance was lost in multivariable analysis (adjusted HR 2.21, 95% CI 0.81-5.99, p=0.121). Among TP53-mutated pts, multihit status did not confer different OS compared with single-hit (HR 1.11, 95% CI 0.41–2.98, p=0.84). Notably, both associations were validated in the Mayo cohort: DNMT3A HR 0.28, p=0.02; TP53 HR 1.92; p=0.03.
Molecular subgroups defined by the two informative genes showed divergent outcomes (log-rank p=0.003): median OS was not reached in TP53-/DNMT3A+ (n=9); it was 13.0 months in TP53-/DNMT3A- (n=57), and 3.6 months in TP53+/DNMT3A- (n=23); TP53+/DNMT3A+ (n=3) had intermediate survival (25.0 months). DNMT3A retained prognostic value among TP53-wild-type pts (not reached vs 13.0 months, p=0.033).
Conclusions. In the prospective ENABLE trial, TP53 and DNMT3A emerged as independent molecular determinants of survival in MPN-BP pts treated with VEN/HMA, and were externally validated (Mayo cohort). In contrast to de novo AML, the favorable impact of DNMT3A mutations likely reflects the distinctive co-mutational context of MPN-BP. The unsatisfactory performance of available scores developed for de novo AML, further underscores the unique genomic landscape of MPN-BP. Larger studies are warranted to confirm these findings and develop a more informative molecular prognostic model for MPN-BP pts treated with venetoclax-based regimens.
DISCLOSURES
Francesca Crupi, MD: No relevant conflicts of interest to declare.